Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This document aims to provide practical guidance for the assessment and management of patients with thrombocytopenia, with a particular focus on immune thrombocytopenia (ITP), during the COVID-19 pandemic. The intention is to support clinicians and, although recommendations have been provided, it is not a formal guideline. Nor is there sufficient evidence base to conclude that alternative approaches to treatment are incorrect. Instead, it is a consensus written by clinicians with an interest in ITP or coagulation disorders and reviewed by members of the UK ITP forum.

Original publication




Journal article


Br J Haematol

Publication Date





1038 - 1043


ITP, TPO RA, intravenous immunoglobulin, platelets, steroids, thrombosis, Adult, Betacoronavirus, COVID-19, Coronavirus Infections, Female, Humans, Male, Pandemics, Pneumonia, Viral, Practice Guidelines as Topic, Purpura, Thrombocytopenic, Idiopathic, SARS-CoV-2